Literature DB >> 15177291

The effect of variation within inhibitory domains on the activity of pea protease inhibitors from the Bowman-Birk class.

Alfonso Clemente1, Donald A MacKenzie, David J Jeenes, Claire Domoney.   

Abstract

We have investigated the properties of variant pea seed protease inhibitors, homologous to the anti-carcinogenic Bowman-Birk inhibitor (BBI) from soybean but differing most significantly in amino acid sequences at the two independent sites of protease inhibition. The pea protease inhibitors were expressed, using Aspergillus niger, with yields of up to 23 mg secreted recombinant protein per litre of media. The recombinant proteins showed protease inhibitory activity and were deduced to be disulphide-bonded correctly; limited post-translational processing had occurred at the amino-terminal ends of all proteins. Differences in trypsin and chymotrypsin specific inhibitory activities, and in inhibition constants, were observed in studies of the two recombinant variants and BBI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177291     DOI: 10.1016/j.pep.2004.03.015

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

1.  Bowman-Birk inhibitors in Lens: identification and characterization of two paralogous gene classes in cultivated lentil and wild relatives.

Authors:  Gabriella Sonnante; Angelo De Paolis; Domenico Pignone
Journal:  Theor Appl Genet       Date:  2005-01-18       Impact factor: 5.699

Review 2.  Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents.

Authors:  Alfonso Clemente; Maria del Carmen Arques
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Eliminating anti-nutritional plant food proteins: the case of seed protease inhibitors in pea.

Authors:  Alfonso Clemente; Maria C Arques; Marion Dalmais; Christine Le Signor; Catherine Chinoy; Raquel Olias; Tracey Rayner; Peter G Isaac; David M Lawson; Abdelhafid Bendahmane; Claire Domoney
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.